Search

Filgotinib

In contrast, the newly approved filgotinib is a highly selective JAK1 inhibitor. … Rheumatoid arthritis (RA) is a chronic, autoimmune, systemic, and inflammatory disease that causes synovial joint symptoms and can limit range of motion in severe cases.

Fremanezumab

[L11779] Along with other recently approved anti-CGRP therapies such as [galcanezumab], [erenumab], and the oral CGRP antagonist [ubrogepant], fremanezumab represents an important step forward in the treatment … [L11749] It was developed by Teva Pharmaceuticals USA and approved by the FDA in September 2018.

Penbutolol

This binding characteristic of penbutolol is being investigated for its implications in Antidepressant Therapy. … Penbutolol is a drug in the beta-blocker class used to treat hypertension. Penbutolol binds both beta-1 and beta-2 adrenergic receptors, rendering it a non-selective beta-blocker.

Afamitresgene autoleucel

[L51114] MAGE-A4 is an intracellular cancer-testis antigen that is overexpressed by cancer cells in synovial sarcoma. … antigen A4 (MAGE-A4)-directed genetically modified autologous T cell immunotherapy product consisting of CD4 and CD8 positive T cells transduced with a self-inactivating lentiviral vector (LV) expressing an

Fibrinogen human

It works by replacing a specific protein in the blood, fibrinogen (factor I), that helps with blood clotting. … It is indicated for the treatment of acute bleeding episodes in patients with both acquired and congenital fibrinogen deficiency, including afibrinogenemia and hypofibrinogenemia.[L41065]

Scopolamine

[A228763] As an acetylcholine analogue, scopolamine can antagonize muscarinic acetylcholine receptors (mAChRs) in the central nervous system and throughout the body, inducing several therapeutic and adverse … [A228423, A228763] Scopolamine was first synthesized in 1959, but to date, synthesis remains less efficient than extracting scopolamine from plants.

Alcloxa

Sibeprenlimab

[L54633] On November 25, 2025, sibeprenlimab was granted accelerated approval by the FDA to reduce proteinuria in adults with primary IgAN at risk for disease progression.[L54628] … [A274848, A274853, A274858] Elevated APRIL levels are often observed in inflammatory disorders, including immunoglobulin A nephropathy (IgAN).

Imelasomeran

Imelasomeran was first approved in Canada on September 1, 2022, as one-half of Moderna's Spikevax Bivalent COVID-19 mRNA vaccine. … [L45320] It encodes for the viral spike protein of the Omicron BA.1 variant of SARS-CoV-2, a particularly infectious variant of concern first documented in 2021.[L43922]

Human vaccinia virus immune globulin

Nevertheless, VIG by virtue of the way it is produced is a poorly characterized and highly variable human product that is only available in very limited quantities - all factors that may intervene with